-
1دورية أكاديمية
المؤلفون: V. B. Vasilyuk, A. Yu. Boroduleva, P. D. Sobolev, A. G. Nikiforova, V. G. Mozgovaya, O. V. Filon, A. V. Zinkovskaya, V. G. Ignatiev, M. Yu. Samsonov, I. S. Kozlova, E. K. Khanonina
المصدر: Фармация и фармакология (Пятигорск), Vol 10, Iss 6, Pp 562-572 (2023)
مصطلحات موضوعية: covid-19, молнупиравир, биоэквивалентность, фармакокинетика, n-гидроксицитидин, Therapeutics. Pharmacology, RM1-950
وصف الملف: electronic resource
العلاقة: https://www.pharmpharm.ru/jour/article/view/1221Test; https://doaj.org/toc/2307-9266Test; https://doaj.org/toc/2413-2241Test
-
2دورية أكاديمية
المؤلفون: R. A. Oseshnyuk, A. G. Nikiforova, A. Yu. Boroduleva, P. D. Sobolev, S. A. Lesnichuk, B. B. Garyaev, A. A. Abramova, V. G. Mozgovaya, O. V. Filon, A. V. Zinkovskaya, A. N. Dolgorukova, E. K. Khanonina, V. G. Ignatiev, M. Yu. Samsonov, Р. А. Осешнюк, А. Г. Никифорова, А. Ю. Бородулева, П. Д. Соболев, С. А. Лесничук, Б. Б. Гаряев, А. А. Абрамова, В. Г. Мозговая, О. В. Филон, А. В. Зинковская, А. Н. Долгорукова, Е. К. Ханонина, В. Г. Игнатьев, М. Ю. Самсонов
المساهمون: The work was carried out with the financing of the R-Pharm group., Работа выполнялась при финансировании группы компаний АО «Р-Фарм».
المصدر: Pharmacy & Pharmacology; Том 11, № 1 (2023); 62-71 ; Фармация и фармакология; Том 11, № 1 (2023); 62-71 ; 2413-2241 ; 2307-9266 ; undefined
مصطلحات موضوعية: воспроизведенный препарат, bioequivalence, pharmacokinetics, nirmatrelvir, ritonavir, generic drug, биоэквивалентность, фармакокинетика, нирматрелвир, ритонавир
وصف الملف: application/pdf
العلاقة: https://www.pharmpharm.ru/jour/article/view/1259/951Test; https://www.pharmpharm.ru/jour/article/view/1259/952Test; Joyce R.P., Hu V.W., Wang J. The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations // Med. Chem. Res. – 2022. – Vol. 31, No. 10. – P. 1637–1646. DOI:10.1007/s00044-022-02951-6; Vangeel L., Chiu W., De Jonghe S., Maes P., Slechten B., Raymenants J., André E., Leyssen P., Neyts J., Jochmans D. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern // Antiviral. Res. – 2022. – Vol. 198. – Art. ID: 105252. DOI:10.1016/j.antiviral.2022.105252; Marzi M., Vakil M.K., Bahmanyar M., Zarenezhad E. Paxlovid: Mechanism of Action, Synthesis, and In Silico Study // Biomed. Res. Int. – 2022. – Vol. 2022. – Art. ID: 7341493. DOI:10.1155/2022/7341493; Singh R.S.P., Toussi S.S., Hackman F., Chan P.L., Rao R., Allen R., Van Eyck L., Pawlak S., Kadar E.P., Clark F., Shi H., Anderson A.S., Binks M., Menon S., Nucci G., Bergman A. Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir // Clin. Pharmacol. Ther. – 2022. – Vol. 112, No. 1. – P. 101–111. DOI:10.1002/cpt.2603; Catlin N.R., Bowman C.J., Campion S.N., Cheung J.R., Nowland W.S., Sathish J.G., Stethem C.M., Updyke L., Cappon G.D. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal models // Reprod. Toxicol. – 2022. – Vol. 108. – P. 56–61. DOI:10.1016/j.reprotox.2022.01.006; Jeong J.H., Chokkakula S., Min S.C., Kim B.K., Choi W.S., Oh S., Yun Y.S., Kang D.H., Lee O.J., Kim E.G., Choi J.H., Lee J.Y., Choi Y.K., Baek Y.H., Song M.S. Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice // Antiviral. Res. – 2022. – Vol. 208. – Art. ID: 105430. DOI:10.1016/j.antiviral.2022.105430; Greasley S.E., Noell S., Plotnikova O., Ferre R., Liu W., Bolanos B., Fennell K., Nicki J., Craig T., Zhu Y., Stewart A.E., Steppan C.M. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants // J. Biol. Chem. – 2022. – Vol. 298, No. 6. – Art. ID: 101972. DOI:10.1016/j.jbc.2022.101972; Owen D.R., Allerton C.M.N., Anderson A.S., Aschenbrenner L., Avery M., Berritt S., Boras B., Cardin R.D., Carlo A., Coffman K.J., Dantonio A., Di L., Eng H., Ferre R., Gajiwala K.S., Gibson S.A., Greasley S.E., Hurst B.L., Kadar E.P., Kalgutkar A.S., Lee J.C., Lee J., Liu W., Mason S.W., Noell S., Novak J.J., Obach R.S., Ogilvie K., Patel N.C., Pettersson M., Rai D.K., Reese M.R., Sammons M.F., Sathish J.G., Singh R.S.P., Steppan C.M., Stewart A.E., Tuttle J.B., Updyke L., Verhoest P.R., Wei L., Yang Q., Zhu Y. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 // Science. – 2021. – Vol. 374, No. 6575. – P. 1586–1593. DOI:10.1126/science.abl4784; Wen W., Chen C., Tang J., Wang C., Zhou M., Cheng Y., Zhou X., Wu Q., Zhang X., Feng Z., Wang M., Mao Q. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis // Ann. Med. – 2022. – Vol. 54, No. 1. – P. 516–523. DOI:10.1080/07853890.2022.2034936; Drożdżal S., Rosik J., Lechowicz K., Machaj F., Szostak B., Przybyciński J., Lorzadeh S., Kotfis K., Ghavami S., Łos M.J. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment // Drug Resist. Updat. – 2021. – Vol. 59. – Art. ID: 100794. DOI:10.1016/j.drup.2021.100794; Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., Baniecki M., Hendrick V.M., Damle B., Simón-Campos A., Pypstra R., Rusnak J.M.; EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 // N. Engl. J. Med. – 2022. – Vol. 386, No. 15. – P. 1397–1408. DOI:10.1056/NEJMoa2118542; Wong C.K.H., Au I.C.H., Lau K.T.K., Lau E.H.Y., Cowling B.J., Leung G.M. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study // Lancet. – 2022. – Vol. 400, No. 10359. – P. 1213–1222. DOI:10.1016/S0140-6736(22)01586-0; Wong C.K.H., Au I.C.H., Lau K.T.K., Lau E.H.Y., Cowling B.J., Leung G.M. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: a retrospective cohort study // Lancet Infect. Dis. – 2022. – Vol. 22, No. 12. – P. 1681–1693. DOI:10.1016/S1473-3099, No. 22)00507-2; Najjar-Debbiny R., Gronich N., Weber G., Khoury J., Amar M., Stein N., Goldstein L.H., Saliba W. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients // Clin. Infect. Dis. – 2023. – Vol. 76, No. 3. – P. 342–349. DOI:10.1093/cid/ciac443. Erratum in: Clin Infect Dis. – 2023. – Vol. 76, No. 6. – P. 1158–1159.; Dryden-Peterson S., Kim A., Kim A.Y., Caniglia E.C., Lennes I.T., Patel R., Gainer L., Dutton L., Donahue E., Gandhi R.T., Baden L.R., Woolley A.E. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System: A Population-Based Cohort Study // Ann. Intern. Med. – 2023. – Vol. 176, No. 1. – P. 77–84. DOI:10.7326/M22-2141; Yuan Y., Jiao B., Qu L., Yang D., Liu R. The development of COVID-19 treatment // Front. Immunol. – 2023. – Vol. 14. – Art. ID: 1125246. DOI:10.3389/fimmu.2023.1125246; Zhang J.J., Dong X., Liu G.H., Gao Y.D. Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality // Clin. Rev. Allergy Immunol. – 2023. – Vol. 64, No. 1. – P. 90–107. DOI:10.1007/s12016-022-08921-5; Lipsitch M., Krammer F., Regev-Yochay G., Lustig Y., Balicer R.D. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact // Nat. Rev. Immunol. – 2022. – Vol. 22, No. 1. – P. 57–65. DOI:10.1038/s41577-021-00662-4; Reis S., Metzendorf M.I., Kuehn R., Popp M., Gagyor I., Kranke P., Meybohm P., Skoetz N., Weibel S. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19 // Cochrane Database Syst. Rev. – 2022. – Vol. 9, No. 9. – Art. ID: CD015395. DOI:10.1002/14651858.CD015395.pub2; Große-Michaelis I., Proestel S., Rao R.M., Dillman B.S., Bader-Weder S., Macdonald L., Gregory W. MedDRA Labeling Groupings to Improve Safety Communication in Product Labels // Ther. Innov. Regul. Sci. – 2023. – Vol. 57, No. 1. – P. 1–6. DOI:10.1007/s43441-022-00393-1; Ullrich S., Nitsche C. The SARS-CoV-2 main protease as drug target // Bioorg. Med. Chem. Lett. – 2020. – Vol. 30, No. 17. – Art. ID: 127377. DOI:10.1016/j.bmcl.2020.127377; Eng H., Dantonio A.L., Kadar E.P., Obach R.S., Di L., Lin J., Patel N.C., Boras B., Walker G.S., Novak J.J., Kimoto E., Singh R.S.P., Kalgutkar A.S. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans // Drug Metab. Dispos. – 2022. – Vol. 50, No. 5. – P. 576–590. DOI:10.1124/dmd.121.000801; Loos N.H.C., Beijnen J.H., Schinkel A.H. The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism? // Int. J. Mol. Sci. – 2022. – Vol. 23, No. 17. – Art. ID: 9866. DOI:10.3390/ijms23179866; https://www.pharmpharm.ru/jour/article/view/1259Test
الإتاحة: https://doi.org/10.19163/2307-9266-2023-11-1-62-71Test
https://doi.org/10.1007/s00044-022-02951-6Test
https://doi.org/10.1016/j.antiviral.2022.105252Test
https://doi.org/10.1155/2022/7341493Test
https://doi.org/10.1002/cpt.2603Test
https://doi.org/10.1016/j.reprotox.2022.01.006Test
https://doi.org/10.1016/j.antiviral.2022.105430Test
https://doi.org/10.1016/j.jbc.2022.101972Test
https://doi.org/10.1126/science.abl4784Test
https://doi.org/10.1080/07853890.2022.2034936Test